- Home
- VIVS vs APVO Comparison
VIVS vs APVO Comparison
Compare VIVS & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- APVO
- Stock Information
- Founded
- VIVS 2007
- APVO 2016
- Country
- VIVS United States
- APVO United States
- Employees
- VIVS N/A
- APVO N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- APVO Health Care
- Exchange
- VIVS Nasdaq
- APVO Nasdaq
- Market Cap
- VIVS 4.6M
- APVO 4.1M
- IPO Year
- VIVS N/A
- APVO N/A
- Fundamental
- Price
- VIVS $1.77
- APVO $2.00
- Analyst Decision
- VIVS
- APVO Strong Buy
- Analyst Count
- VIVS 0
- APVO 1
- Target Price
- VIVS N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- VIVS 53.7K
- APVO 134.2K
- Earning Date
- VIVS 08-12-2025
- APVO 08-11-2025
- Dividend Yield
- VIVS N/A
- APVO N/A
- EPS Growth
- VIVS N/A
- APVO N/A
- EPS
- VIVS N/A
- APVO N/A
- Revenue
- VIVS $142,000.00
- APVO N/A
- Revenue This Year
- VIVS $42.38
- APVO N/A
- Revenue Next Year
- VIVS $15.42
- APVO N/A
- P/E Ratio
- VIVS N/A
- APVO N/A
- Revenue Growth
- VIVS 94.52
- APVO N/A
- 52 Week Low
- VIVS $1.41
- APVO $1.72
- 52 Week High
- VIVS $21.96
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- VIVS N/A
- APVO 29.31
- Support Level
- VIVS N/A
- APVO $1.72
- Resistance Level
- VIVS N/A
- APVO $2.20
- Average True Range (ATR)
- VIVS 0.00
- APVO 0.18
- MACD
- VIVS 0.00
- APVO 0.01
- Stochastic Oscillator
- VIVS 0.00
- APVO 22.58
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.